Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs. The finding also reveals important limitations in today's artificial intelligence tools for drug discovery. The study, published in the June 2 online issue of the Journal of the American Chemical Society [10.1021/jacs.6c05178], focused on PKMYT1, a type of protein